Key facts

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. Here are some of our key facts and milestones on the way to achieving our purpose.

  • £3.9bn

    R&D investment in 2018

  • 33*

    of the 46* new medicines now in development targeting modulation of the immune system

  • 16*

    immuno-oncology assets now in clinical development

  • £30.8bn

    total turnover in 2018

  • £8.7bn

    adjusted operating profit in 2018

  • £5.7bn

    free cash flow in 2018

  • £3.9bn

    dividends paid in 2018

  • 78%

    employee engagement score on our latest employee survey

  • £224m

    donated in 2018 to community health programmes

  • 1st

    in Access to Medicines Index since the assessment began in 2008

  • 100,000

    we employ around 100,000 people in over 150 countries, with more than a third of these in emerging markets

  • 11,000+

    more than 11,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products

* Includes M7824, the subject of the alliance with Merck KGaA, Darmstadt, Germany, expected to close in Q1 2019.

Find out more about us

*Includes M7824, the subject of the alliance with Merck KGaA, Darmstadt, Germany, expected to close in Q1 2019.